Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

4.553 -0.077 (-1.66%)
Streaming Delayed Price Updated: 9:43 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
From ADC Therapeutics SA
Via Business Wire
30 Stocks Moving In Friday's Mid-Day Session
Gainers ATI Physical Therapy, Inc. (NYSE: ATIP) shares gained 25.2% to $3.8050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.50 to $5.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021
Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE: 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
From ADC Therapeutics
Via Business Wire
ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
From ADC Therapeutics SA
Via Business Wire
71 Biggest Movers From Yesterday
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales... 
Via Benzinga
ADC Therapeutics SA (ADCT) Q3 2021 Earnings Call Transcript
ADCT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021
From ADC Therapeutics SA
Via Business Wire
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
From ADC Therapeutics
Via Business Wire
ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in Morgan Stanley’s 19th Annual Global Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Medical Leadership Transition
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty
ADC Therapeutics SA (NYSE: ADCT) has entered into a royalty purchase agreement with HealthCare Royalty Partners for up to $325 million. ADC Therapeutics... 
Via Benzinga
ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million
From ADC Therapeutics SA
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021
Upgrades DA Davidson upgraded the previous rating for AAON Inc (NASDAQ: 
Via Benzinga
ADC Therapeutics SA (ADCT) Q2 2021 Earnings Call Transcript
ADCT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma
From ADC Therapeutics SA
Via Business Wire
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma
From ADC Therapeutics SA
Via Business Wire
Expert Ratings for ADC Therapeutics
Within the last quarter, ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 2 1... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
From ADC Therapeutics SA
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.